Benjamin Gbolo Zoawe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin Gbolo Zoawe has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Koto-Te-Nyiwa Ngbolua
Université de Kinshasa
4 shared publications - Pius Tshimankinda Mpiana
Conseil Scientifique National
4 shared publications - Damien Sha-Tshibey Tshibangu
Department of Chemistry, Faculty of Sciences, University of Kinshasa
3 shared publications - Pierre Duez
Unit of Therapeutic Chemistry and Pharmacognosy, University of Mons, 7000 Mons, Belgium
3 shared publications - Amandine Nachtergael
Unit of Therapeutic Chemistry and Pharmacognosy, Faculty of Medicine, Pharmacy and Biomedical Sciences, University of Mons (UMONS), Avenue du Champ de Mars, 25, 7000 Mons, Belgium
2 shared publications - Aristote Matondo
Department of Chemistry, Faculty of Sciences and Technology, University of Kinshasa, & Research Centre for Pharmacopoeia and Traditional Medicine (CRPMT), Higher Institute of Medical Techniques of Kinshasa, Kinshasa, Democratic Republic of the Congo
2 shared publications
Latest Publications
- Open Access
- 24 September 2024
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 4 (4) , 387-397
LC-MS/MS Analysis of crude Flavonoid Compounds from Justicia secunda from Democratic Republic of the Congo and evaluation of their antisickling Activity
Justicia secunda Vahl (Acanthaceae) is a tropical herbaceous plant traditionally used by indigenous peoples of the Democratic Republic of the Congo (DRC) to treat symptoms associated with sickle cell disease (SCD), a genetic condition with life-threatening complications. Given the lack of side-effect-free drugs, alternative herbal therapies that can reduce or reverse red blood cell sickling may serve as safe and effective treatments. The primary objective of this study is to conduct a phytochemical screening of crude flavonoids extracted from J. secunda using LC-ESI/MS/MS. J. secunda extracts were evaluated for their phytoconstituents and anti-sickling properties. The anti-sickling properties were assessed through reverse sickling estimation, polymerization and oxidation inhibition, and osmotic fragility assays. Fractionation of the methanol extract and chemical profiling were performed by flash chromatography and high-performance thin-layer chromatography analysis respectively. Characterization and identification of the crude flavonoids were done using chromatography and spectroscopy methods. Chemical screening of crude flavonoids revealed the presence of 12 flavonoid O-glycosides based on one flavonol (methoxy-kaempferol) and two flavones (luteolin and apigenin). The crude flavonoid extracts demonstrated maximum reversal of sickled red blood cells (91.9 ± 0.8%), significant inhibition of hemoglobin polymerization (77.8 ± 7.6%) and hemoglobin S auto-oxidation (96.3 ± 0.2), and provided maximum protection of red blood cells against hyperhemolysis. The results validate the traditional use of J. secunda and identify potential compounds for the development of novel anti-sickling agents.
- 24 September 2024
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 4 (4) , 387-397
Open AccessLC-MS/MS Analysis of crude Flavonoid Compounds from Justicia secunda from Democratic Republic of the Congo and evaluation of their antisickling Activity
Justicia secunda Vahl (Acanthaceae) is a tropical herbaceous plant traditionally used by indigenous peoples of the Democratic Republic of the Congo (DRC) to treat symptoms associated with sickle cell disease (SCD), a genetic condition with life-threatening complications. Given the lack of side-effect-free drugs, alternative herbal therapies that can reduce or reverse red blood cell sickling may serve as safe and effective treatments. The primary objective of this study is to conduct a phytochemical screening of crude flavonoids extracted from J. secunda using LC-ESI/MS/MS. J. secunda extracts were evaluated for their phytoconstituents and anti-sickling properties. The anti-sickling properties were assessed through reverse sickling estimation, polymerization and oxidation inhibition, and osmotic fragility assays. Fractionation of the methanol extract and chemical profiling were performed by flash chromatography and high-performance thin-layer chromatography analysis respectively. Characterization and identification of the crude flavonoids were done using chromatography and spectroscopy methods. Chemical screening of crude flavonoids revealed the presence of 12 flavonoid O-glycosides based on one flavonol (methoxy-kaempferol) and two flavones (luteolin and apigenin). The crude flavonoid extracts demonstrated maximum reversal of sickled red blood cells (91.9 ± 0.8%), significant inhibition of hemoglobin polymerization (77.8 ± 7.6%) and hemoglobin S auto-oxidation (96.3 ± 0.2), and provided maximum protection of red blood cells against hyperhemolysis. The results validate the traditional use of J. secunda and identify potential compounds for the development of novel anti-sickling agents.
- Open Access
- 16 February 2023
- Published by Universitas Muhammadiyah Yogyakarta in Journal of Fundamental and Applied Pharmaceutical Science
- Vol. 3 (2) , 64-82
In Vitro Biological Activities of Drepanoalpha® Ethanolic Extract, A Justicia Secunda and Moringa Oleifera-Based Phytomedicine Proposed for The Symptomatic Treatment of Sickle Cell Disease
Sickle cell disease (SCD) is an autosomal recessive blood disorder characterized by red blood cells that assume an abnormal, rigid sickle shape under low-oxygen conditions. These sickle-shaped erythrocytes tend to lyse, aggregate, and obstruct small blood vessels, leading to major complications. The present study aims to investigate properties that may underlie the activity of Drepanoalphaâ, an antisickling herbal formulation developed in the Democratic Republic of Congo (DRC) for the prevention and symptomatic treatment of sickle cell disease crises. The Drepanoalpha® Ethanolic Extract (DEE) is a dry extract (drug-extract ratio, DER, 100/11) prepared from ethanol (96 %, v/v) percolation of a 1:1 mixture of 2 food plants, Justicia secunda Vahl and Moringa oleifera Lam. Sickling was classically measured by light microscopy on diluted washed erythrocytes obtained from homozygote patients; erythrocytes were treated with 2 % Na2S2O5 in the presence of DEE (suspension in 9 ‰ NaCl), 9 ‰ NaCl (negative control) or disodium cromoglycate (DSCG, positive control). For all tested conditions, the sickle hemoglobin polymerization, the Fe2+/Fe3+ ratio, and the median corpuscular fragility were measured by spectrophotometry. The DEE reversed sickling by 89.1 %, comparable to DSCG (87.7 %; 60.3 µg/mL), inhibiting sickle cell hemoglobin polymerization of 77.8 % and 74.4 %, respectively. The Fe2+/Fe3+ ratio was improved by 18.0 % for DEE and 15.9 % for DSCG. The median corpuscular fragility values were 0.602, 0.714, and 0.732 for NaCl 9 ‰, DSCG, and DEE, respectively. The measured in vitro parameters validate an effective antisickling effect of DEE and confirm the value of this improved traditional herbal formulation for the management of SCD.
- 16 February 2023
- Published by Universitas Muhammadiyah Yogyakarta in Journal of Fundamental and Applied Pharmaceutical Science
- Vol. 3 (2) , 64-82
Open AccessIn Vitro Biological Activities of Drepanoalpha® Ethanolic Extract, A Justicia Secunda and Moringa Oleifera-Based Phytomedicine Proposed for The Symptomatic Treatment of Sickle Cell Disease
Sickle cell disease (SCD) is an autosomal recessive blood disorder characterized by red blood cells that assume an abnormal, rigid sickle shape under low-oxygen conditions. These sickle-shaped erythrocytes tend to lyse, aggregate, and obstruct small blood vessels, leading to major complications. The present study aims to investigate properties that may underlie the activity of Drepanoalphaâ, an antisickling herbal formulation developed in the Democratic Republic of Congo (DRC) for the prevention and symptomatic treatment of sickle cell disease crises. The Drepanoalpha® Ethanolic Extract (DEE) is a dry extract (drug-extract ratio, DER, 100/11) prepared from ethanol (96 %, v/v) percolation of a 1:1 mixture of 2 food plants, Justicia secunda Vahl and Moringa oleifera Lam. Sickling was classically measured by light microscopy on diluted washed erythrocytes obtained from homozygote patients; erythrocytes were treated with 2 % Na2S2O5 in the presence of DEE (suspension in 9 ‰ NaCl), 9 ‰ NaCl (negative control) or disodium cromoglycate (DSCG, positive control). For all tested conditions, the sickle hemoglobin polymerization, the Fe2+/Fe3+ ratio, and the median corpuscular fragility were measured by spectrophotometry. The DEE reversed sickling by 89.1 %, comparable to DSCG (87.7 %; 60.3 µg/mL), inhibiting sickle cell hemoglobin polymerization of 77.8 % and 74.4 %, respectively. The Fe2+/Fe3+ ratio was improved by 18.0 % for DEE and 15.9 % for DSCG. The median corpuscular fragility values were 0.602, 0.714, and 0.732 for NaCl 9 ‰, DSCG, and DEE, respectively. The measured in vitro parameters validate an effective antisickling effect of DEE and confirm the value of this improved traditional herbal formulation for the management of SCD.
- Open Access
- 16 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (2) , 265-273
Glucose oxidase as a model enzyme for antidiabetic activity evaluation of medicinal plants: In vitro and in silico evidence
Diabetes mellitus is a major public health problem in the world. In Africa, more than 80% of patients use plants for their treatment. However, the methods of validation of endogenous knowledge usually used are costly. The alternative method developed in this study aims at creating hyperglycemia in vitro and exploiting the metabolic pathway involving glucose oxidase for UV-visible spectrophotometric screening of medicinal plants’ antidiabetic activity. The evolution of glucose oxidation as a function of drug concentration is followed by UV-visible spectrophotometry. The formation of the stable complex between the enzyme and the inhibitor is studied using molecular docking. Drugs used (Gliben) and plant extracts exhibited an in vitro hypoglycemic effect by reducing exponentially, in vitro, the level of free glucose. The results also showed that L. multiflora is more active than V. amygdalina (IC50: 1.36 ± 0.09 mg/mL Vs IC50: 3.00 ± 0.54 mg/mL). Gliben (0.5 mg/mL) and L. multiflora (2 mg/mL) reduced both the rate of oxidation of glucose by glucose oxidase (catalytic power Vmax: 0.84 ± 0.11 mg*mL-1*min-1 for Gliben and 1.72 ± 0.13 mg*mL-1*min-1 for L. multiflora); and the affinity of this enzyme for its substrate-glucose (KM: 15.11 ± 2.72 mg*mL-1 for Gliben and 9.17 ± 1.56 mg*mL-1 for L. multiflora) when these results are compared to enzyme catalysis in the absence of inhibitor (Vmax: 2.86 ± 0.44 mg*mL-1*min-1; KM: 8.07 ± 1.96 mg*mL-1). The binding of GOX (1GAL) to selected phytocompounds derived from L. multiflora was confirmed by molecular docking. The most stable complexes were obtained for four compounds; 8 (-10.1±0.0 Kcal/mol), 6 (-9.5±0.1 Kcal/mol), 3 (-8.3±0.0 Kcal/mol) and 9 (-8.2±0.1 Kcal/mol). Among these, compounds 8 and 6 formed complexes with the enzyme stabilized by hydrogen bonds, the compound 8 forms 5 hydrogen bonds (ASN514, ASP424, ARG95, TYP68, LEU65) while compound 6 forms 2 hydrogen bonds (ASN514 and SER422). However, no H-bonding interaction occurs in the complex that involves ligands 9 and 3 despite their high binding energy (-8.2±0.1 Kcal/mol and -8.3±0.0 Kcal/mol respectively). Glucose oxidase can serve as a marker enzyme for in vitro antidiabetic activity evaluation of medicinal plants.
- 16 January 2022
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 2 (2) , 265-273
Open AccessGlucose oxidase as a model enzyme for antidiabetic activity evaluation of medicinal plants: In vitro and in silico evidence
Diabetes mellitus is a major public health problem in the world. In Africa, more than 80% of patients use plants for their treatment. However, the methods of validation of endogenous knowledge usually used are costly. The alternative method developed in this study aims at creating hyperglycemia in vitro and exploiting the metabolic pathway involving glucose oxidase for UV-visible spectrophotometric screening of medicinal plants’ antidiabetic activity. The evolution of glucose oxidation as a function of drug concentration is followed by UV-visible spectrophotometry. The formation of the stable complex between the enzyme and the inhibitor is studied using molecular docking. Drugs used (Gliben) and plant extracts exhibited an in vitro hypoglycemic effect by reducing exponentially, in vitro, the level of free glucose. The results also showed that L. multiflora is more active than V. amygdalina (IC50: 1.36 ± 0.09 mg/mL Vs IC50: 3.00 ± 0.54 mg/mL). Gliben (0.5 mg/mL) and L. multiflora (2 mg/mL) reduced both the rate of oxidation of glucose by glucose oxidase (catalytic power Vmax: 0.84 ± 0.11 mg*mL-1*min-1 for Gliben and 1.72 ± 0.13 mg*mL-1*min-1 for L. multiflora); and the affinity of this enzyme for its substrate-glucose (KM: 15.11 ± 2.72 mg*mL-1 for Gliben and 9.17 ± 1.56 mg*mL-1 for L. multiflora) when these results are compared to enzyme catalysis in the absence of inhibitor (Vmax: 2.86 ± 0.44 mg*mL-1*min-1; KM: 8.07 ± 1.96 mg*mL-1). The binding of GOX (1GAL) to selected phytocompounds derived from L. multiflora was confirmed by molecular docking. The most stable complexes were obtained for four compounds; 8 (-10.1±0.0 Kcal/mol), 6 (-9.5±0.1 Kcal/mol), 3 (-8.3±0.0 Kcal/mol) and 9 (-8.2±0.1 Kcal/mol). Among these, compounds 8 and 6 formed complexes with the enzyme stabilized by hydrogen bonds, the compound 8 forms 5 hydrogen bonds (ASN514, ASP424, ARG95, TYP68, LEU65) while compound 6 forms 2 hydrogen bonds (ASN514 and SER422). However, no H-bonding interaction occurs in the complex that involves ligands 9 and 3 despite their high binding energy (-8.2±0.1 Kcal/mol and -8.3±0.0 Kcal/mol respectively). Glucose oxidase can serve as a marker enzyme for in vitro antidiabetic activity evaluation of medicinal plants.
- Open Access
In vivo Evaluation and in silico Prediction of the Toxicity of Drepanoalpha Hard capsules
This study was carried out in order to investigate the safety of Drepanoalpha hard hard capsules, a phytomedicine used for the management of sickle cell disease in the Democratic Republic of Congo by the acute and sub-acute administration in Guinea pigs. The hard capsules were dissolved in saline normal solution (NaCl 0.9 %). The animals were randomly selected, marked and divided into 2 groups of 5 animals each (3 males and 2 females) for acute toxicity and 4 groups of 3 animals each for sub-acute toxicity. Those received by gavage a single dose of 5000 mg/kg body weight (B.W.) of Drepanoalpha hard capsules for acute toxicity followed by 125 mg/Kg, 250 mg/Kg and 500 mg/Kg B.W. twice daily for 28 days for sub-acute toxicity and saline normal solution (NaCl 0.9 % solution as vehicle). Hematological, biochemical and histopathological analyses were performed and the behavior of the animals was observed after treatment. The results showed that 50 % of the lethal dose (LD50) is greater than 5000 mg/Kg B.W., and the relative weights of vital organs (kidney, liver, lungs, and heart) collected from Guinea pigs at the end of treatment on D14 (acute toxicity) and D28 (sub-acute toxicity) did not undergone significant changes (p>0.05). The results of haematological (Red Blood Cells, White Blood Cells, Haemoglobin, Haematocrit) and biochemical (ALT, AST, Albumin, Total Protein) tests did not show significant differences between the control and test groups at significance level (0.05 for acute toxicity), while the histopathological study revealed none damage to the various organs excised. In conclusion, the results confirm the safety of Drepanoalpha, as shown in previous studies with lyophilisate and decocate in rats and Guinea pigs.
Open AccessIn vivo Evaluation and in silico Prediction of the Toxicity of Drepanoalpha Hard capsules
This study was carried out in order to investigate the safety of Drepanoalpha hard hard capsules, a phytomedicine used for the management of sickle cell disease in the Democratic Republic of Congo by the acute and sub-acute administration in Guinea pigs. The hard capsules were dissolved in saline normal solution (NaCl 0.9 %). The animals were randomly selected, marked and divided into 2 groups of 5 animals each (3 males and 2 females) for acute toxicity and 4 groups of 3 animals each for sub-acute toxicity. Those received by gavage a single dose of 5000 mg/kg body weight (B.W.) of Drepanoalpha hard capsules for acute toxicity followed by 125 mg/Kg, 250 mg/Kg and 500 mg/Kg B.W. twice daily for 28 days for sub-acute toxicity and saline normal solution (NaCl 0.9 % solution as vehicle). Hematological, biochemical and histopathological analyses were performed and the behavior of the animals was observed after treatment. The results showed that 50 % of the lethal dose (LD50) is greater than 5000 mg/Kg B.W., and the relative weights of vital organs (kidney, liver, lungs, and heart) collected from Guinea pigs at the end of treatment on D14 (acute toxicity) and D28 (sub-acute toxicity) did not undergone significant changes (p>0.05). The results of haematological (Red Blood Cells, White Blood Cells, Haemoglobin, Haematocrit) and biochemical (ALT, AST, Albumin, Total Protein) tests did not show significant differences between the control and test groups at significance level (0.05 for acute toxicity), while the histopathological study revealed none damage to the various organs excised. In conclusion, the results confirm the safety of Drepanoalpha, as shown in previous studies with lyophilisate and decocate in rats and Guinea pigs.